Inspection Readiness
FDA to Begin Unannounced Inspections of Non-U.S. Manufacturing Facilities
Beginning August 2025, FDA inspections at non-U.S. manufacturing sites will take place without advance notice. This shift eliminates prior warning and signals a new standard for global regulatory oversight—one that demands continuous readiness.
With deep FDA expertise and regulatory professionals positioned around the world, ProPharma helps pharmaceutical, biotechnology, and medical device companies build and sustain inspection readiness—before the FDA arrives.
FDA to Begin Unannounced Inspections of Non-U.S. Manufacturing Facilities
Beginning August 2025, FDA inspections at non-U.S. manufacturing sites will take place without advance notice. This shift eliminates prior warning and signals a new standard for global regulatory oversight—one that demands continuous readiness.
With deep FDA expertise and regulatory professionals positioned around the world, ProPharma helps pharmaceutical, biotechnology, and medical device companies build and sustain inspection readiness—before the FDA arrives.
Inspection Readiness is not an option – now, more than ever, it is urgent.
Our team of experts is equipped to guide you through every step of any inspection your firm is facing, with experience and expertise. The overview below outlines how ProPharma supports clients through every stage of the inspection readiness lifecycle.

We ensure that every step towards Inspection Readiness is carefully calibrated to your needs. Our method is backed by tangible tools and training programs developed from the ground up, tailored not just to your product, but to your organization's unique scale and scope. This approach allows you to maintain focus on running your business, while we dedicate ourselves fully to your Inspection Readiness, making it our singular priority.
Inspection Readiness Experts
Unannounced inspections are coming. Preparation can't wait.
With global regulatory and quality expertise and a history of guiding clients through successful FDA inspections, ProPharma helps ensure your operations are always inspection ready—no matter when the FDA arrives.
Secure Your Regulatory Inspection Success
On average a new product takes approximately 10-15 years to develop, whether it is a biologic, a pharmaceutical product, a medical device, or a combination thereof.
- Can you risk the time and resources you invested in development by ignoring the importance of Inspection Readiness for a new product?
- Can you risk having an existing product off the market for remediation activities following a For Cause Inspection?
- Can your patients?
ProPharma's expertise covers all aspects of Inspections. Inspection Readiness Evaluation, Project Management, your Inspection Program/Process, Logistics, and Training – are just some of the most important areas of Inspection Readiness. Our expertise can become your greatest asset. We are eager to become your partner in navigating this critical process.
PAI Readiness
Pre-approval Inspections are one of the most critical inspections any Biologic, Pharmaceutical or Medical Device firm will undertake. Failure to meet FDA expectations can have a huge impact on organizations, including:
- Delays to product launch.
- Thousands, if not millions of dollars, in remediation costs.
- Lost market share.
- Loss of a firm's credibility.
PAI readiness is critical, and ProPharma is an industry leader in providing PAI Readiness to our clients.
BIMO Readiness
BIMO inspection readiness is essential for sponsors to ensure compliance with FDA regulations, protect data integrity, and uphold patient safety standards. By preparing thoroughly, sponsors:
- Ensure compliance with FDA regulations.
- Protect data integrity.
- Uphold patient safety standards.
- Help avoid costly delays.
- Prevent potential compliance issues.
- Facilitate smoother FDA inspections.
To date, we have had a 100% success rate on PAI Readiness projects for our clients
News & Insights
October 21, 2026
From Defensible to Predictive: How High-Functioning MLR Teams Are Evolving Their...
Recent FDA enforcement activity is changing how MLR teams assess promotional risk. Learn why organizations are moving from defensible claims to predictive, enforcement-informed risk assessment.
October 19, 2026
AI-Readiness 101: AI Success Starts with Understanding Your Data
Unlock AI success by understanding your data. Learn the foundations of AI readiness and how to build trust in your data for reliable insights.
July 8, 2026
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...
ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.
June 18, 2026
ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...
ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
October 20, 2026
Accelerating Clinical Trial Activation Across Latin America
Launching clinical trials across multiple countries requires navigating varying regulatory requirements, site contracts, translations, import/export processes, and site engagement activities, all...
September 18, 2026
Flexible Resourcing Without Limits: Scaling Capabilities Across the Development ...
Development complexity doesn’t increase in a straight line. As programs progress from discovery through Phase III, submission, and post-approval, demands for medical writing, biometrics, clinical...
August 3, 2026
Achieving Continuous Audit Readiness Across a Global Medical Information Program
Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...
December 2, 2026
Beyond the Buzz: Leveraging Community Management to Enhance Medical Information
Patients, caregivers, and healthcare professionals are increasingly turning to digital channels to seek information, share experiences, and discuss treatments. Join this webinar to explore how...
November 12, 2026
Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance
Sites are being asked to do more than ever before while balancing increasing trial complexity, patient expectations, and operational demands. Join this webinar to explore how flexible, integrated...
News & Insights
September 18, 2026
Flexible Resourcing Without Limits: Scaling Capabilities Across the Development ...
Development complexity doesn’t increase in a straight line. As programs progress from discovery through Phase III, submission, and post-approval, demands for medical writing, biometrics, clinical...
August 3, 2026
Achieving Continuous Audit Readiness Across a Global Medical Information Program
Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...
November 12, 2026
Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance
Sites are being asked to do more than ever before while balancing increasing trial complexity, patient expectations, and operational demands. Join this webinar to explore how flexible, integrated...